Global Regulatory Updates on Clinical Trials (February 2026)
Written by: Blaine Van Leuven, MS, MBA, RAC
Executive Director, Regulatory and Strategic Development
February 2026 saw several targeted regulatory updates affecting Phase I–IV drug and biologic clinical trials. The FDA’s move to default to a single pivotal trial for marketing authorization approval marked the most significant shift in global regulations, while China’s NMPA issued multiple trial design and safety guidance, Health Canada advanced DSMB oversight expectations, and ICH reinforced safety reporting standards. Together, these changes signal continued evolution in evidentiary and safety requirements across global development programs.
FDA (US)
Final updates
Shift to One Adequate and Well-Controlled Clinical Trial as the Default for Drug Approval
The FDA published an official policy in February 2026 stating that, as a default, one adequate and well-controlled pivotal clinical trial (supported by confirmatory evidence) will be accepted as the primary basis for marketing approval of new drug and biologic license applications in place of the traditionally expected two-trial standard. This recalibrates how “substantial evidence” for effectiveness is interpreted and can affect Phase III clinical strategy and overall development timelines and costs for drug and biologic sponsors.
Link to article in the New England Journal of Medicine
(Note on practice) Although legal authority to approve products based on a single trial with confirmatory evidence has existed since 1997, this 2026 statement formally positions the one-trial standard as the default interpretation of the statutory requirement for “substantial evidence,” potentially impacting Phase III–IV evidence expectations.
Draft updates
Draft System for Customized / Bespoke Therapies (Proposed Framework)
The FDA proposed a new regulatory pathway to accelerate development and approval of customized or “bespoke” therapies, particularly ultra-rare disease treatments, including gene editing. The framework is intended to allow commercialization based on evidence from very small patient numbers where traditional large clinical trials aren’t feasible, and it is open for public comment through a 60-day period after Feb 23, 2026.
European Medicines Agency (EMA)
Final updates
No new EMA final clinical trial regulatory updates specific to Phase I–IV drug/biologic trials were published during February 2026 in the publicly searchable CTIS/clinical trial guidance listings.
Draft updates
No new EMA clinical trial draft consultation documents were identified in the February 2026 period that directly change Phase I–IV requirements.
(Latest CTIS support and guidance updates appear unchanged in Feb 2026 published materials.)
National Medical Products Administration (NMPA – China)
Final updates
慢性失眠治疗药物临床试验技术指导原则（试行）
Technical guidance for clinical trial design of chronic insomnia treatments was finalized, detailing key trial endpoints and design expectations, with relevance to Phase II–III trial planning.
抑郁障碍治疗药物临床试验技术指导原则（试行） — 修订发布通告（2026年第11号）
Revised technical guidance for depression treatment clinical trials was issued, emphasizing evidence expectations and design elements chiefly in Phase III confirmatory stages.
化学仿制药透皮和局部给药系统黏附性和刺激性/致敏性评估临床试验技术指导原则（试行）
Guidance on clinical evaluation of adhesion, dermal irritation and sensitization for generic transdermal/topical systems, with implications for bioequivalence and clinical testing often overlapping Phase I safety/PK and confirmatory studies.
新药全球同步研发中基于多区域临床试验数据进行获益–风险评估的指导原则（试行）
Principles for benefit–risk assessment using multi-regional clinical trial (MRCT) data, shaping requirements for integrated Phase II–III evidence packages in global submissions.
研发期间安全性更新报告的问答文件
Questions and Answers on Development Safety Update Reports (DSURs)
Q&A clarifying expectations for Development Safety Update Reports (DSURs), affecting ongoing safety reporting across the lifecycle of Phase I–IV programs.
Draft updates
No new draft clinical trial-focused guidance was identified for NMPA/CDE during this period.
Therapeutic Goods Administration (TGA) – Australia
Final updates
No new TGA phase-specific clinical trial regulatory updates were published in February 2026.
Draft updates
No TGA clinical trial draft consultations appeared in February 2026 source listings.
(Note: TGA updated its adoption timeline for ICH E6(R3) before February 2026 but not within this period.)
Health Canada
Final updates
No finalized Health Canada guidance specific to clinical trial phases published during February 2026 was located.
Draft updates
Draft Guidance: Establishment and Operation of a Data and Safety Monitoring Board (GUI-0100)
Draft guidance proposing updated expectations for setup, responsibilities and reporting of DSMBs for clinical trials, which will impact safety governance and data monitoring across Phase I–IV studies once finalized.
International Council for Harmonisation (ICH)
Final updates
Final Training Module for ICH E2B(R3)
ICH issued a final training module to support implementation of the E2B(R3) guideline on electronic transmission of individual case safety reports, affecting how serious adverse event data are communicated during clinical development (Phase I–IV).
Draft updates
No new draft clinical trial guideline documents from ICH with first publication in February 2026 were identified.